Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis

Hui Bu50 enrolled

Overview

The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Meningeal Carcinomatosis

Interventions

methotrexateDRUG

The quantity of methotrexate is different in the two groups.

Eligibility

Sex: ALLMin age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age 14 or more * a history of solid tumor * a new clinical neurological signs and symptoms * a typical CT(Computerized Tomography,CT) or MRI(Magnetic Resonance Imaging,MRI) imaging findings * tumor cells in cerebrospinal fluid Exclusion Criteria: * KPS score \<60 * the tumor patients with organ failure * bacteria, fungi or viral meningitis

Outcomes

Primary Outcomes

overall survival

Time frame: one year

Secondary Outcomes

The incidence of adverse reactions

In accordance with the standard of CTCAE, an assessment will be assessed every month

Time frame: one year

KPS score

In accordance with the standard of KPS(Karnofsky Performance Status,KPS) score, an assessment will be assessed every month

Time frame: one year

Central Contacts

Hui Bu

CONTACT

86-13831106903 buhuimy1@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.